{"id":"etv-or-tdf","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Diarrhea"},{"rate":"6%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ETV is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of viral DNA.","oneSentence":"Inhibits viral replication","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:19.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT07169656","phase":"","title":"Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-06-03","conditions":"Chronic Hepatitis b","enrollment":15000},{"nctId":"NCT05769816","phase":"PHASE2","title":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)","status":"RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-10","conditions":"Chronic Hepatitis b, Anti-PD-1 Antibody","enrollment":120},{"nctId":"NCT05771402","phase":"PHASE2","title":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)","status":"RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-10","conditions":"Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα","enrollment":120},{"nctId":"NCT07120750","phase":"","title":"Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma (HCC), Chronic Hepatitis B","enrollment":332},{"nctId":"NCT07095855","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08","conditions":"Chronic Hepatitis B","enrollment":1300},{"nctId":"NCT07079150","phase":"","title":"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-01-01","conditions":"Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)","enrollment":1500},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT07007286","phase":"","title":"Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-06","conditions":"HBV, HCC","enrollment":1500},{"nctId":"NCT05123599","phase":"PHASE1","title":"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-06","conditions":"Hepatitis B, Chronic","enrollment":24},{"nctId":"NCT02496897","phase":"PHASE1","title":"Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2015-07","conditions":"Hepatitis B","enrollment":61},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT06926647","phase":"","title":"A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-05-01","conditions":"HBV, Chronic Hepatitis b","enrollment":2000},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT05275023","phase":"PHASE2","title":"An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-30","conditions":"Hepatitis B, Chronic","enrollment":37},{"nctId":"NCT04129554","phase":"PHASE2","title":"A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-11-06","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT03982186","phase":"PHASE2","title":"A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-08-01","conditions":"Hepatitis B, Chronic","enrollment":471},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT02883647","phase":"","title":"Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2014-01-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT05404919","phase":"PHASE2","title":"Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2022-09-06","conditions":"Lung Transplant, Hepatitis B","enrollment":""},{"nctId":"NCT03887702","phase":"PHASE3","title":"Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2020-01-17","conditions":"Hepatitis B Infection, Malignant Solid Neoplasm","enrollment":4},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT02650271","phase":"PHASE3","title":"Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC","status":"COMPLETED","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":240},{"nctId":"NCT04820686","phase":"PHASE2","title":"A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-05-07","conditions":"Chronic Hepatitis B","enrollment":65},{"nctId":"NCT03905655","phase":"PHASE2","title":"Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2019-10-22","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT04680598","phase":"","title":"Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-25","conditions":"Hepatocellular Carcinoma","enrollment":800},{"nctId":"NCT05965388","phase":"","title":"Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy","status":"NOT_YET_RECRUITING","sponsor":"Wen-hong Zhang","startDate":"2023-12-01","conditions":"HBV, HCC","enrollment":5000},{"nctId":"NCT05937178","phase":"","title":"Real-world Study Optimizing Nucleotide-analogues","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-31","conditions":"Hepatitis B, Chronic","enrollment":20000},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT05808335","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2022-01-11","conditions":"Chronic Hepatitis B","enrollment":32},{"nctId":"NCT03780543","phase":"PHASE2","title":"A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2018-12-20","conditions":"Chronic Hepatitis B","enrollment":92},{"nctId":"NCT05793268","phase":"NA","title":"Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"E-DA Hospital","startDate":"2022-12-20","conditions":"Chronic Hepatitis b","enrollment":360},{"nctId":"NCT04864366","phase":"","title":"Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-04-30","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT05721300","phase":"NA","title":"Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer","status":"UNKNOWN","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2023-02-10","conditions":"Hepatocellular Carcinoma, Chronic Hepatitis B","enrollment":2215},{"nctId":"NCT05376124","phase":"","title":"Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-01-01","conditions":"Hepatitis B, Chronic, Virus Diseases","enrollment":110},{"nctId":"NCT05661786","phase":"","title":"Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-12","conditions":"Chronic Hepatitis b","enrollment":4500},{"nctId":"NCT03361956","phase":"PHASE2","title":"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-02-13","conditions":"Hepatitis B","enrollment":232},{"nctId":"NCT04465916","phase":"PHASE2","title":"Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)","status":"TERMINATED","sponsor":"Enyo Pharma","startDate":"2020-05-12","conditions":"Hepatitis B, Chronic","enrollment":26},{"nctId":"NCT04454567","phase":"PHASE2","title":"A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-11-11","conditions":"Chronic Hepatitis B","enrollment":2},{"nctId":"NCT05256823","phase":"PHASE2","title":"Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Lai Wei","startDate":"2022-02-24","conditions":"To Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues in Nucleos(t)Ide-treated Patients With Chronic Hepatitis B","enrollment":47},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT05357183","phase":"","title":"The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2022-01-01","conditions":"Chronic Hepatitis B","enrollment":1200},{"nctId":"NCT02224456","phase":"PHASE4","title":"Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-25","conditions":"Hepatitis B, Chronic","enrollment":197},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT04886336","phase":"","title":"The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-06-04","conditions":"HBV","enrollment":250},{"nctId":"NCT03241641","phase":"PHASE4","title":"Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.","status":"COMPLETED","sponsor":"Young-Suk Lim","startDate":"2017-10-26","conditions":"Chronic Hepatitis b","enrollment":174},{"nctId":"NCT03576066","phase":"PHASE2","title":"A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-11","conditions":"Chronic Hepatitis B","enrollment":73},{"nctId":"NCT04189276","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Tasly Tianjin Biopharmaceutical Co., Ltd.","startDate":"2019-12-10","conditions":"Hepatitis B Virus (HBV)","enrollment":100},{"nctId":"NCT04201808","phase":"PHASE4","title":"Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides","status":"UNKNOWN","sponsor":"New Discovery LLC","startDate":"2021-05-01","conditions":"Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT04501224","phase":"NA","title":"The Efficacy and Safety of TAF vs Other NAs in Patients With LVL","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-08-03","conditions":"Chronic Hepatitis b, Cirrhosis Due to Hepatitis B","enrollment":200},{"nctId":"NCT04539119","phase":"PHASE3","title":"Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-07-03","conditions":"B-cell Lymphoma, HBV","enrollment":120},{"nctId":"NCT04157257","phase":"PHASE2","title":"An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-07-26","conditions":"Chronic Hepatitis b","enrollment":60},{"nctId":"NCT01943799","phase":"PHASE2","title":"Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-13","conditions":"Chronic HBV Infection","enrollment":178},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT04034368","phase":"PHASE4","title":"A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2019-08","conditions":"HBV","enrollment":8},{"nctId":"NCT03945487","phase":"PHASE2","title":"Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2019-05-20","conditions":"Decompensated Liver Cirrhosis","enrollment":200},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT02167113","phase":"","title":"Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay","status":"COMPLETED","sponsor":"Hologic, Inc.","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":331},{"nctId":"NCT02019966","phase":"","title":"A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-05-12","conditions":"The Difficult-to-treat Chronic Hepatitis B","enrollment":1020},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT02391805","phase":"PHASE2","title":"A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-17","conditions":"Hepatitis B, Chronic","enrollment":31},{"nctId":"NCT03357822","phase":"PHASE4","title":"A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2018-01-25","conditions":"Chronic Hepatitis B","enrollment":2000},{"nctId":"NCT03032536","phase":"PHASE1","title":"Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers","status":"TERMINATED","sponsor":"Alios Biopharma Inc.","startDate":"2017-01-31","conditions":"Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B","enrollment":54},{"nctId":"NCT03274427","phase":"PHASE3","title":"Treatment of Intermediate-stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2017-07-18","conditions":"HCC","enrollment":300},{"nctId":"NCT03278444","phase":"PHASE3","title":"Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2017-07-18","conditions":"HCC","enrollment":300},{"nctId":"NCT01715987","phase":"","title":"Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment","status":"TERMINATED","sponsor":"New Discovery LLC","startDate":"2012-10","conditions":"Hepatitis B","enrollment":48},{"nctId":"NCT01706575","phase":"PHASE2","title":"A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-01","conditions":"Hepatitis B, Chronic","enrollment":76},{"nctId":"NCT03042481","phase":"","title":"Off-therapy Response After Stopping Entecavir or Tenofovir","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-04","conditions":"Chronic Hepatitis b","enrollment":400},{"nctId":"NCT03018821","phase":"NA","title":"The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Xi'an Traditional Medicine Hospital","startDate":"2017-01","conditions":"Hepatitis B， Chronic","enrollment":250},{"nctId":"NCT02973646","phase":"PHASE4","title":"Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT02288208","phase":"PHASE1","title":"Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B","status":"TERMINATED","sponsor":"TetraLogic Pharmaceuticals","startDate":"2014-11","conditions":"Hepatitis B","enrollment":7},{"nctId":"NCT02005146","phase":"","title":"Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-12","conditions":"Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues","enrollment":86},{"nctId":"NCT02238860","phase":"PHASE4","title":"A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Asian Institute Of Medical Sciences","startDate":"2014-09","conditions":"Cirrhosis Due to Hepatitis B","enrollment":100},{"nctId":"NCT00662545","phase":"PHASE4","title":"Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"HIV Infections, Hepatitis B","enrollment":10},{"nctId":"NCT00298363","phase":"PHASE2","title":"Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-04","conditions":"Chronic Hepatitis B","enrollment":112},{"nctId":"NCT01027065","phase":"PHASE1, PHASE2","title":"Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2009-12","conditions":"Chronic Hepatitis B","enrollment":24},{"nctId":"NCT00994773","phase":"PHASE1","title":"Simvastatin for the Treatment of Chronic Hepatitis B","status":"COMPLETED","sponsor":"Bader, Ted, M.D.","startDate":"2009-12","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT01595633","phase":"PHASE4","title":"Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-03","conditions":"Chronic Hepatitis B","enrollment":124},{"nctId":"NCT01588912","phase":"PHASE4","title":"Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir","status":"UNKNOWN","sponsor":"Pusan National University Yangsan Hospital","startDate":"2012-04","conditions":"Chronic Hepatitis B","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8398,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ETV or TDF","genericName":"ETV or TDF","companyName":"Tasly Tianjin Biopharmaceutical Co., Ltd.","companyId":"tasly-tianjin-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Inhibits viral replication Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}